Q4 2024 Dyadic International Inc Earnings Call Transcript
Key Points
- Dyadic International Inc (DYAI) reported strong revenue performance in 2024, including $1.9 million in milestone and license payments.
- The company is advancing its dual-track strategy by commercializing near-term non-pharmaceutical products while building a robust biopharmaceutical pipeline.
- Dyadic is strengthening its global impact through partnerships with academia, industry, government, and leading nonprofit organizations like the Gates Foundation and SEPI.
- The company is making significant progress in the life sciences segment with the development of DNA and RNA-related reagent enzymes, offering a scalable recurring revenue opportunity.
- Dyadic received a $4.5 million grant from SEPI and a $3 million grant from the Gates Foundation, supporting the development of vaccines and monoclonal antibodies.
- Despite increased revenue, Dyadic International Inc (DYAI) reported a net loss of approximately $5.8 million for the year ended December 31, 2024.
- Research and development expenses decreased significantly, which may indicate a reduction in ongoing R&D activities.
- The commercialization of some products, such as recombinant human serum albumin, is still pending and expected in 2025, indicating potential delays.
- The company faces regulatory hurdles in the commercialization of certain products, such as dairy enzymes, which require specific approvals.
- Dyadic's focus on non-pharmaceutical products may divert resources from its biopharmaceutical pipeline, potentially impacting long-term growth in that segment.
Good evening and welcome to Diadic International's year-end 2024 conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this conference call is being recorded as of today, March 26, 2025. I would now like to turn the call over to Ms. Ping Rawson, the addict's Chief Financial Officer. Please go ahead.
Thank you. Good evening and welcome everyone to Daic International's full year 2024 conference call. I hope you have had the chance to review that press releases announcing financial results for the physical year ended December 31, 2024. You may access our press release on Form 10K and the investor session of the company's website at dyadic.com.
On today's call, our President and CEO Mark Imofar and our Chief Operating Officer, Joe Hazleton will give a review of our 2024 business and corporate highlights and provide a commentary on the strategic direction of the business.
I will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
